<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301286</url>
  </required_header>
  <id_info>
    <org_study_id>P14.152</org_study_id>
    <nct_id>NCT02301286</nct_id>
  </id_info>
  <brief_title>A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients</brief_title>
  <acronym>ASPIRIN</acronym>
  <official_title>A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting voor Patienten met Kanker aan het Spijsverteringskanaal (SPKS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Geriatrische Oncologie Nederland (GeriOnNe)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonds NutsOhra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovatiefonds Zorgverzekeraars</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether acetylsalicylic acidis effective on the
      recurrence and survival of colon cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effect of 80mg acetylsalicylic acid (given
      orally once daily for 5 years) on 5 year overall survival (OS) for stage II and III colon
      cancer patients of 45 years of age and older. Preclinical, epidemiologic and clinical
      evidence suggest that acetylsalicylic acid use may reduce overall cancer risk and mortality
      in colon cancer patients. It is a phase III double blind placebo controlled, randomized trial
      of adjuvant low-dose acetylsalicylic acid in colon cancer patients. Patients will be
      stratified at randomization by centre, age (&lt;70 and ≥70 years) chemotherapy use (any versus
      none) and disease stage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5 year overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time to an event for OS is defined as the time interval between the date of randomisation and the date of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time to an event for DFS is defined as the time interval between the date of randomisation and the date of disease recurrence or death, whichever comes first. Recurrence of a disease can be a loco-regional recurrence, a distant recurrence or a new primary colon cancer. The evidence for recurrence must be documented in the patients' file.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>5 years</time_frame>
    <description>The time elapsed between randomisation until treatment discontinuation due to disease progression, unacceptable toxicity, death or any other event of interest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1588</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Adjuvant Therapy</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Acetylsalicylic acid</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥45 years

          -  Patients must have TNM stage that is one of the following: pT3-4; N0-2 and M0, or
             pT1-2 and N1-2 (UICC stage II and III) (in case of &gt;1 tumour: largest tumour is stage
             II or III)

          -  Patients must have completed surgical resection (R0) (both laparoscopic and open
             surgery) within 12 weeks of randomisation

        Exclusion Criteria:

          -  Patients with rectal cancer (defined as tumour within 15 cm from the anal verge)

          -  Patients currently taking oral anti-coagulants or use of LMWH

          -  Patients currently taking acetylsalicylic acid for any reason

          -  Patients with a history of bleeding disorders or active gastric or duodenal ulcers

          -  Patients currently taking high dose systemic glucocorticoids.(≥ 30 mg predniso(lo)n)

          -  Patients with (suspected) (non-) polyposis syndrome (FAP/AFAP, MAP, Lynch syndrome)

          -  Patients with &gt;100 polyps of the colon or a known hereditary syndrome of the colon in
             a first degree family member

          -  Allergy or intolerance to salicylates.

          -  Patients with a history of other malignancies in the last 5 years, except for SCC or
             CIN.

          -  Presence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G.J. Liefers, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J.E.A. Portielje, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Fodde, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medisch Centrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J.P.B.M. Braak</last_name>
    <phone>0031715263500</phone>
    <email>datacenter@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.A. Kouwenhoven, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meander MC</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.C.J. Consten, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Festen, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Nieboer, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O.J.L. Loosveld, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IJsselland Ziekenhuis</name>
      <address>
        <city>Capelle aan den IJssel</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D.F.S. Kehrer, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.W.T. Dekker, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L.W. Kessels, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Slingeland Ziekenhuis</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Van Arkel, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NijSmellinghe</name>
      <address>
        <city>Drachten</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Van Der Mijle, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Baars, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.J. Creemers, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maxima MC</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.D. Slooter, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MST</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.B. Van Duyn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruijter Ziekenhuis</name>
      <address>
        <city>Goes</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.K. Halteren, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatrix Ziekenhuis</name>
      <address>
        <city>Gorinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Davidis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C.I.M. Baeten, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.B.A.C. Stockmann, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis St. Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Temizkan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elkerliek Ziekenhuis</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Vincent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. De Valk, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.J. Liefers, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne Ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P.A. Neijenhuis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HMC</name>
      <address>
        <city>Leidschendam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.W.K.S. Marinelli, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MC Zuiderzee</name>
      <address>
        <city>Lelystad</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.M. Smeenk, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Los, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Toorenvliet, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.J. Veldhuis, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZorgSaam Zeeuws Vlaanderen</name>
      <address>
        <city>Terneuzen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Van Dijk, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>M.P.S. Sie, MD PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HAGA ziekenhuis</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.E.A. Portielje, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ETZ</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.J. Van Alphen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.J. Van De Wouw, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Streekziekenhuis Koningin Beatrix (SKB)</name>
      <address>
        <city>Winterswijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P.P.J.B.M. Schiphorst, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lange Land Ziekenhuis</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.J.M. Van der Pas, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>GJLiefers</investigator_full_name>
    <investigator_title>Surgical Oncologist</investigator_title>
  </responsible_party>
  <keyword>Acetylsalicylic acid</keyword>
  <keyword>Colon cancer</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

